Abstract:T-cells genetically engineered to express a chimeric antigen receptor (CAR) have shown remarkable results in patients with B-cell malignancies, including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma, with some promising efficacy in patients with multiple myeloma. However, the efficacy of CAR T-cell therapy is still hampered by local immunosuppression and significant toxicities, notably cytokine release syndrome (CRS) and neurotoxicity. The tumor microenvironment (TME) has been identified to play a major role in preventing durable responses to immunotherapy in both solid and hematologic malignancies, with this role exaggerated in solid tumors. The TME comprises a diverse set of components, including a heterogeneous population of various cells and acellular elements that collectively contribute towards the interplay of pro-immune and immunosuppressive signaling. In particular, macrophages, myeloid-derived suppressor cells, regulatory T-cells, and cell-free factors such as cytokines are major contributors to local immunosuppression in the TME of patients treated with CAR T-cells. In order to create a more favorable niche for CAR T-cell function, armored CAR T-cells and other combinatorial approaches are being explored for potential improved outcomes compared to conventional CAR T-cell products. While these strategies may potentiate CAR T-cell function and efficacy, they may paradoxically increase the risk of adverse events due to increased pro-inflammatory signaling. Herein, we discuss the mechanisms by which the TME antagonizes CAR T-cells and how innovative immunotherapy strategies are being developed to address this roadblock. Furthermore, we offer perspective on how these novel approaches may affect the risk of adverse events, in order to identify ways to overcome these barriers and expand the clinical benefits of this treatment modality in patients with diverse cancers. Precise immunomodulation to allow for improved tumor control while simultaneously mitigating the toxicities seen with current generation CAR T-cells is integral for the future application of more effective CAR T-cells against other malignancies.

Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Optimising CAR T therapy for the treatment of solid tumors

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel

Cutting-Edge CAR Engineering: Beyond T Cells

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors

Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer

Navigating CAR-T cells through the solid-tumour microenvironment

A long way to the battlefront: CAR T cell therapy against solid cancers.

Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

Bright future or blind alley? CAR-T cell therapy for solid tumors